查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
歐洲藥物動力學服務市場預測至 2031 年 - 區域分析 - 按藥物類型、服務類型、治療應用和最終用戶
市場調查報告書
商品編碼
1597065

歐洲藥物動力學服務市場預測至 2031 年 - 區域分析 - 按藥物類型、服務類型、治療應用和最終用戶

Europe Pharmacokinetics Services Market Forecast to 2031 - Regional Analysis - by Drug Type, Service Type, Therapeutic Application, and End User
出版日期: | 出版商: The Insight Partners | 英文 87 Pages | 訂單完成後即時交付

價格

2023年歐洲藥物動力學服務市值為2.2216億美元，預計2031年將達到3.8738億美元；預計2023年至2031年複合年成長率為7.2%。

將藥物動力學服務外包給 CRO 推動歐洲藥物動力學服務市場

將藥物動力學服務外包給合約研究組織 (CRO) 為藥廠和申辦者提供了多種優勢。他們可以透過選擇這些服務來實現經濟高效的營運。此外，他們可以專注於靈活工作並為其核心營運帶來可擴展性，同時實現快速週轉時間。外包幫助製藥公司專注於產品商業化，同時實施能力建構、降低成本和資料管理等措施。藥物發現過程很複雜，任何錯誤或錯誤結果都可能導致巨大的成本並延遲該過程。 CRO 聘用經驗豐富的科學家和研究人員，他們在藥物動力學和其他領域擁有專業知識。因此，它們為製藥公司提供了獲得其專業知識的機會，從而消除了投資僱用此類熟練勞動力或提供額外培訓來培養他們的需要。因此，擁有有前景的候選藥物但資源有限的小型公司和參與多角化經營的大公司都選擇由組織良好的CRO提供的臨床研究服務，這支持了歐洲藥物動力學服務市場。

歐洲藥物動力學服務市場概況

歐洲藥物動力學服務市場分為德國、法國、英國、西班牙、義大利和歐洲其他地區。德國和義大利等國家預計將佔據該地區市場的重要佔有率，法國、英國和西班牙等國家可能在藥物動力學服務方面擁有成長機會。隨著新藥開發臨床試驗數量的增加，以及擴大採用體內和體外模型來了解藥物動力學變異性，歐洲藥物動力學服務市場預計在未來幾年將會成長。

歐洲藥物動力學服務市場收入及 2031 年預測（百萬美元）

歐洲藥物動力學服務市場細分

歐洲藥物動力學服務市場分為藥物類型、服務類型、治療應用、最終用戶和國家。

根據藥物類型，歐洲藥物動力學服務市場分為小分子、大分子和疫苗。 2023 年，小分子細分市場佔據最大的市場佔有率。

從服務類型來看，歐洲藥物動力學服務市場分為臨床前ADME和人體研究、PK/PD分析和報告、給藥模擬、風險分析等。 2023 年，臨床前 ADME 和人體研究領域佔據最大的市場佔有率。

依治療應用，歐洲藥物動力學服務市場分為腫瘤學、傳染病、神經系統疾病、自體免疫疾病、婦科疾病、心血管疾病、呼吸系統疾病等。 2023 年，腫瘤學領域佔據最大的市場佔有率。

依最終用戶分類，歐洲藥物動力學服務市場分為製藥和生物技術公司、合約研究組織等。 2023 年，合約研究組織細分市場佔據最大的市場佔有率。

依國家/地區分類，歐洲藥物動力學服務市場分為德國、法國、英國、義大利、西班牙和歐洲其他地區。 2023 年，法國在歐洲藥物動力學服務市場佔有率中佔據主導地位。

查爾斯河實驗室國際公司； Eurofins Scientific SE； Evotec SE；塞塔拉公司； Parexel國際公司；賽默飛世爾科技公司；艾倫特；太平洋生物實驗室；和 SGS SA 是歐洲藥物動力學服務市場上的一些領先公司。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 主要見解

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：歐洲藥物動力學服務市場 - 主要市場動態

  • 市場促進因素
    • 慢性病和傳染病的盛行率上升
    • 擴大藥物動力學研究的應用範圍
    • 將藥物動力學服務外包給 CRO
  • 市場限制
    • 新興國家藥物動力學服務提供者的覆蓋範圍有限
  • 市場機會
    • 擴大採用體內和體外模型來了解藥物動力學的變異性
  • 未來趨勢
    • 藥物動力學服務中越來越多採用巨量資料分析
  • 促進因素和限制的影響：

第 5 章：藥物動力學服務市場 - 歐洲分析

  • 歐洲藥物動力學服務市場收入，2021-2031

第 6 章：歐洲藥物動力學服務市場分析 - 按藥物類型

  • 概述
  • 小分子
  • 大分子
  • 疫苗

第 7 章：歐洲藥物動力學服務市場分析 - 按服務類型

  • 概述
  • 臨床前 ADME 和人體研究
  • PK/PD 分析和報告
  • 劑量模擬
  • 風險分析
  • 其他

第 8 章：歐洲藥物動力學服務市場分析 - 按治療應用

  • 腫瘤學
  • 傳染病
  • 神經系統疾病
  • 自體免疫疾病
  • 婦科疾病
  • 心血管疾病
  • 呼吸系統疾病
  • 其他

第 9 章：歐洲藥物動力學服務市場分析 - 按最終用戶

  • 製藥和生物技術公司
  • 合約研究組織
  • 其他

第 10 章：歐洲藥物動力學服務市場 - 國家分析

  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其餘的

第 11 章：公司簡介

  • Charles River Laboratories International Inc
  • Eurofins Scientific SE
  • Evotec SE
  • Certara Inc.
  • Parexel International Corp
  • Thermo Fisher Scientific Inc.
  • Allucent
  • PACIFIC BIOLABS
  • SGS SA

第 12 章：附錄

Product Code: BMIRE00030902

The Europe pharmacokinetics services market was valued at US$ 222.16 million in 2023 and is expected to reach US$ 387.38 million by 2031; it is estimated to register a CAGR of 7.2% from 2023 to 2031.

Outsourcing of Pharmacokinetics Services to CROs Drives Europe Pharmacokinetics Services Market

Outsourcing pharmacokinetics services to contract research organizations (CROs) offers several advantages to drug manufacturers and sponsors. They can operate cost-effectively by opting for these services. Moreover, they can focus on working flexibly and bringing scalability to their core operations, alongside achieving fast turnaround time. Outsourcing helps pharmaceutical companies to focus on product commercialization while implementing measures for capacity building, cost reduction, and data management. The drug discovery process is complex, and any error or false result can lead to significant costs and delay the process. CROs employ experienced scientists and researchers who hold expertise in pharmacokinetics and other fields. Thus, they provide pharma companies with access to their expertise, thereby eliminating the need to invest in hiring such skilled workforces or providing extra training to build them. Therefore, small companies with promising drug candidates but limited resources and large companies involved in diversifying their operations are opting for clinical research services provided by well-organized CROs, which bolsters the Europe pharmacokinetics services market.

Europe Pharmacokinetics Services Market Overview

The Europe pharmacokinetics services market is segmented into Germany, France, the UK, Spain, Italy, and the Rest of Europe. Countries such as Germany and Italy are expected to account significant contributors share of the market in the region, and countries such as France, the UK, and Spain are likely to have growth opportunities for pharmacokinetics services. The European pharmacokinetics services market is expected to grow in the coming years with the rising number of clinical trials for new drug development, and the increasing adoption of in-vivo and in-vitro models for understanding pharmacokinetics variability.

Europe Pharmacokinetics Services Market Revenue and Forecast to 2031 (US$ Million)

Europe Pharmacokinetics Services Market Segmentation

The Europe pharmacokinetics services market is categorized into drug type, service type, therapeutic application, end user, and country.

Based on drug type, the Europe pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held the largest market share in 2023.

In terms of service type, the Europe pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held the largest market share in 2023.

By therapeutic application, the Europe pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynaecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held the largest market share in 2023.

By end user, the Europe pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held the largest market share in 2023.

By country, the Europe pharmacokinetics services market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. France dominated the Europe pharmacokinetics services market share in 2023.

Charles River Laboratories International Inc; Eurofins Scientific SE; Evotec SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; and SGS SA are some of the leading companies operating in the Europe pharmacokinetics services market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Pharmacokinetics Services Market - Key Market Dynamics

  • 4.1 Market Drivers
    • 4.1.1 Rising Prevalence of Chronic and Infectious Diseases
    • 4.1.2 Expanding Range of Application of Pharmacokinetic Studies
    • 4.1.3 Outsourcing of Pharmacokinetics Services to CROs
  • 4.2 Market Restraints
    • 4.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
  • 4.3 Market Opportunities
    • 4.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
  • 4.4 Future Trend
    • 4.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
  • 4.5 Impact of Drivers and Restraints:

5. Pharmacokinetics Services Market - Europe Analysis

  • 5.1 Europe Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031

6. Europe Pharmacokinetics Services Market Analysis - by Drug Type

  • 6.1 Overview
  • 6.2 Small Molecule
    • 6.2.1 Overview
    • 6.2.2 Small Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.3 Large Molecule
    • 6.3.1 Overview
    • 6.3.2 Large Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.4 Vaccines
    • 6.4.1 Overview
    • 6.4.2 Vaccines: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

7. Europe Pharmacokinetics Services Market Analysis - by Service Type

  • 7.1 Overview
  • 7.2 Pre-Clinical ADME and Human Studies
    • 7.2.1 Overview
    • 7.2.2 Pre-Clinical ADME and Human Studies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 PK/PD Analysis and Reporting
    • 7.3.1 Overview
    • 7.3.2 PK/PD Analysis and Reporting: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Dosing Simulations
    • 7.4.1 Overview
    • 7.4.2 Dosing Simulations: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Risk Analysis
    • 7.5.1 Overview
    • 7.5.2 Risk Analysis: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8. Europe Pharmacokinetics Services Market Analysis - by Therapeutic Application

  • 8.1 Oncology
    • 8.1.1 Overview
    • 8.1.2 Oncology: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Infectious Diseases
    • 8.2.1 Overview
    • 8.2.2 Infectious Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Neurological Disorders
    • 8.3.1 Overview
    • 8.3.2 Neurological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Autoimmune Diseases
    • 8.4.1 Overview
    • 8.4.2 Autoimmune Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Gynecological Disorders
    • 8.5.1 Overview
    • 8.5.2 Gynecological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.6 Cardiovascular Diseases
    • 8.6.1 Overview
    • 8.6.2 Cardiovascular Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.7 Respiratory Disorders
    • 8.7.1 Overview
    • 8.7.2 Respiratory Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.8 Others
    • 8.8.1 Overview
    • 8.8.2 Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9. Europe Pharmacokinetics Services Market Analysis - by End User

  • 9.1 Pharmaceutical and Biotechnology Companies
    • 9.1.1 Overview
    • 9.1.2 Pharmaceutical and Biotechnology Companies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Contract Research Organization
    • 9.2.1 Overview
    • 9.2.2 Contract Research Organization: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Others
    • 9.3.1 Overview
    • 9.3.2 Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10. Europe Pharmacokinetics Services Market - Country Analysis

  • 10.1 Europe
    • 10.1.1 Europe Pharmacokinetics Services Market Breakdown by Countries, 2023 and 2031 (%)
      • 10.1.1.1 Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.1.1 Overview
        • 10.1.1.1.2 Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.1.3 Germany: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
        • 10.1.1.1.4 Germany: Europe Pharmacokinetics Services Market Breakdown, by Service Type
        • 10.1.1.1.5 Germany: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 10.1.1.1.6 Germany: Europe Pharmacokinetics Services Market Breakdown, by End User
      • 10.1.1.2 France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.2.1 Overview
        • 10.1.1.2.2 France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.2.3 France: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
        • 10.1.1.2.4 France: Europe Pharmacokinetics Services Market Breakdown, by Service Type
        • 10.1.1.2.5 France: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 10.1.1.2.6 France: Europe Pharmacokinetics Services Market Breakdown, by End User
      • 10.1.1.3 United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.3.1 Overview
        • 10.1.1.3.2 United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.3.3 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
        • 10.1.1.3.4 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Service Type
        • 10.1.1.3.5 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 10.1.1.3.6 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by End User
      • 10.1.1.4 Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.4.1 Overview
        • 10.1.1.4.2 Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.4.3 Italy: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
        • 10.1.1.4.4 Italy: Europe Pharmacokinetics Services Market Breakdown, by Service Type
        • 10.1.1.4.5 Italy: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 10.1.1.4.6 Italy: Europe Pharmacokinetics Services Market Breakdown, by End User
      • 10.1.1.5 Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.5.1 Overview
        • 10.1.1.5.2 Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.5.3 Spain: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
        • 10.1.1.5.4 Spain: Europe Pharmacokinetics Services Market Breakdown, by Service Type
        • 10.1.1.5.5 Spain: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 10.1.1.5.6 Spain: Europe Pharmacokinetics Services Market Breakdown, by End User
      • 10.1.1.6 Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.6.1 Overview
        • 10.1.1.6.2 Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
        • 10.1.1.6.3 Rest of Europe Pharmacokinetics Services Market Breakdown, by Drug Type
        • 10.1.1.6.4 Rest of Europe Pharmacokinetics Services Market Breakdown, by Service Type
        • 10.1.1.6.5 Rest of Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
        • 10.1.1.6.6 Rest of Europe Pharmacokinetics Services Market Breakdown, by End User

11. Company Profile

  • 11.1 Charles River Laboratories International Inc
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Eurofins Scientific SE
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Evotec SE
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Certara Inc.
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
  • 11.5 Parexel International Corp
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Thermo Fisher Scientific Inc.
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Allucent
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 PACIFIC BIOLABS
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 SGS SA
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms for Pharmacokinetic Services Market

List Of Tables

  • Table 1. Europe Pharmacokinetics Services Market Segmentation
  • Table 2. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 3. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 4. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 5. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 6. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 7. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 8. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 9. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 10. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 11. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 12. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 13. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 14. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 15. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 16. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 17. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 18. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 19. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 20. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 21. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 22. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
  • Table 23. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
  • Table 24. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
  • Table 25. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 26. Glossary of Terms

List Of Figures

  • Figure 1. Europe Pharmacokinetics Services Market Segmentation, by Country
  • Figure 2. Europe Pharmacokinetics Services Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Europe Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
  • Figure 5. Europe Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)
  • Figure 6. Small Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Large Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Vaccines: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Europe Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)
  • Figure 10. Pre-Clinical ADME and Human Studies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. PK/PD Analysis and Reporting: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Dosing Simulations: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Risk Analysis: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Europe Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)
  • Figure 16. Oncology: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Infectious Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Neurological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Autoimmune Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. Gynecological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Cardiovascular Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Respiratory Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Europe Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)
  • Figure 25. Pharmaceutical and Biotechnology Companies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Contract Research Organization: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 28. Europe Pharmacokinetics Services Market - Revenue by Key Countries Revenue 2023 (US$ Million)
  • Figure 29. Europe Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 30. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 31. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 32. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 33. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 34. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 35. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)